peptides - Blogging About What's Possible

Recent posts

Biopharma’s Future: Next-Generation LC-MS Workflows for Peptide MAM

By March 18, 2021
LC-MS workflows for peptide MAM

The development of biotherapeutics continues to accelerate with their potential to revolutionize disease treatment in areas not adequately addressed by small molecule therapeutics. However, the complexity of these macromolecules and the range of potential modification… Read more >

Categories: Pharmaceutical, Technologies
Tags: , , , , , , , ,

Comprehending COVID-19: How Consumables Can Increase LC-MS/MS Sensitivity

By January 19, 2021

During 2020, we collaborated with many of our customers to develop targeted liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS) methods to detect SARS-CoV-2 (the virus that causes COVID-19) from biological samples. However, the combination of the biological… Read more >

Categories: Chemical, COVID-19, Technologies
Tags: , , , , ,

New Preparative Chromatography Learning Tool: Peptide Isolation Primer

By May 10, 2017

As the interest in peptides as potential drug candidates increases, the need for basic information about the isolation and purification of these peptides also grows.

Categories: Technologies
Tags: , , , , , ,

Webinar Highlights: Advanced Techniques in Peptide Isolation

By October 10, 2016

Hello, I’m Andy Aubin, Principal Consulting Chemist at Waters.  Jo-Ann Jablonski, Principal Scientist at Waters, and I recently conducted a webinar that addressed some techniques to make peptide purifications more efficient. We discussed three techniques:… Read more >

Categories: Technologies
Tags: , , , , ,

Three Reasons for Biopharmaceutical Labs to Add Mass Detection to Routine Analyses

By March 9, 2016

As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?

Categories: Pharmaceutical, Technologies
Tags: , , , , , , , , , , , , , , , , , ,